These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19922456)

  • 21. Reduced CSF CART in dementia with Lewy bodies.
    Schultz K; Wiehager S; Nilsson K; Nielsen JE; Lindquist SG; Hjermind LE; Andersen BB; Wallin A; Nilsson C; Petersén A
    Neurosci Lett; 2009 Apr; 453(2):104-6. PubMed ID: 19356602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Cepek L; Bibl M; Wiltfang J; Schulz-Schaeffer WJ; Ciesielczyk B; Neumann M; Steinacker P; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Dement Geriatr Cogn Disord; 2005; 19(2-3):164-70. PubMed ID: 15637452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dementia with Lewy Bodies and its differentiation from Alzheimer's disease].
    Ransmayr G; Katzenschlager R; Dal-Bianco P; Wenning G; Bancher C; Jellinger K; Schmidt R; Poewe W
    Neuropsychiatr; 2007; 21(2):63-74. PubMed ID: 17640492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged.
    Timmer NM; Herbert MK; Claassen JA; Kuiperij HB; Verbeek MM
    Neurobiol Aging; 2015 Mar; 36(3):1271-3. PubMed ID: 25577411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
    Kaufer DI
    Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():32-9. PubMed ID: 14676467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Depression in dementia with Lewy bodies].
    Sakai K; Yamane Y; Yamamoto Y; Maeda K
    Seishin Shinkeigaku Zasshi; 2013; 115(11):1127-34. PubMed ID: 24450145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
    Hansson SF; Andréasson U; Wall M; Skoog I; Andreasen N; Wallin A; Zetterberg H; Blennow K
    J Alzheimers Dis; 2009; 16(2):389-97. PubMed ID: 19221428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
    Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
    Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative electroencephalogram analysis in dementia with Lewy bodies and Alzheimer's disease.
    Kai T; Asai Y; Sakuma K; Koeda T; Nakashima K
    J Neurol Sci; 2005 Oct; 237(1-2):89-95. PubMed ID: 16019033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.
    Parnetti L; Lanari A; Amici S; Gallai V; Vanmechelen E; Hulstaert F;
    Neurol Sci; 2001 Feb; 22(1):77-8. PubMed ID: 11487210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies.
    Boström F; Hansson O; Blennow K; Gerhardsson L; Lundh T; Minthon L; Zetterberg H; Londos E
    Dement Geriatr Cogn Disord; 2009; 28(4):314-9. PubMed ID: 19844105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An aberrant protein complex in CSF as a biomarker of Alzheimer disease.
    Lovell MA; Lynn BC; Xiong S; Quinn JF; Kaye J; Markesbery WR
    Neurology; 2008 Jun; 70(23):2212-8. PubMed ID: 18448869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies.
    Higuchi M; Tashiro M; Arai H; Okamura N; Hara S; Higuchi S; Itoh M; Shin RW; Trojanowski JQ; Sasaki H
    Exp Neurol; 2000 Apr; 162(2):247-56. PubMed ID: 10739631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and treatment of Lewy body dementia].
    Madsen AM; Lomholt RK; Djernes JK
    Ugeskr Laeger; 2002 Apr; 164(18):2383-6. PubMed ID: 12024840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.